Nancy Boman News Today

Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1 study for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL); Next data update expected in Q2 2023Announced preclinical data for differentiated chimeric antigen receptor (CAR) and chimeric adaptor (CAd) progr...

01.12.2022 - Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on November 30, 2022. Three individuals hired by ...